Other languages Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Market Closed - Hong Kong S.E. Other stock markets 09:08:10 21/05/2024 BST			5-day change	1st Jan Change
1.88 ^HKD	-4.08%		+4.44%	-48.07%

05-13	Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab	MT
05-10	Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab	05-13
Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	05-10
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22%	05-07
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint	05-01
Jacobio Pharmaceuticals Plans Auditor Change	04-25
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention	04-09
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting	04-09
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses	04-01
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16%	03-01
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300	03-01
Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress	02-19
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13%	02-19
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor	02-18
Jacobio Presents Clinical Data on Pancreatic Cancer Treatment at Oncology Meet; Shares Fall 7%	01-22
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI	01-19
Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium	12-07
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo	22/10/23
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23
Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients	07/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Other languages

Filters